EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Emmaus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026
- Market cap
- $6.03M
- P/E (TTM)
- –
- Dividend yield
- –
Emmaus Life Sciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Endari - U.S. [Member] | $9.05M | $13.48M | $22.00M | – | – | – | – | – | 72.7% | -32.9% |
| Endari - International [Member] | $3.18M | $2.67M | $6.96M | – | – | – | – | – | 25.5% | +19.1% |
| Other [Member] | $225.00K | $506.00K | $636.00K | $536.00K | $493.00K | $603.00K | $441.00K | – | 1.8% | -55.5% |
| Neurometric Services [Member] | – | – | – | – | – | – | – | $128.50K | – | – |
| Endari [Member] | – | – | $28.96M | $17.85M | $20.12M | $22.56M | $22.31M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Emmaus Life Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.